title: Possible benefits of azilsartan compared with other angiotensin II type 1 receptor blockers.
authors.affiliation: 1] Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan [2] Department of Molecular Cardiovascular Therapeutics, Fukuoka University School of Medicine, Fukuoka, Japan [3] Department of Molecular Cardiology, Cleveland Clinic Foundation, Cleveland, OH, USA.
authors.forename: Shin-Ichiro
authors.initials: S
authors.lastname: Miura
authors.affiliation: 1] Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan [2] Department of Molecular Cardiovascular Therapeutics, Fukuoka University School of Medicine, Fukuoka, Japan.
authors.forename: Keijiro
authors.initials: K
authors.lastname: Saku
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D010069:Oxadiazoles / Q000627:therapeutic use*; D013777:Tetrazoles / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D010069:Oxadiazoles; D013777:Tetrazoles; C521273:azilsartan; C077793:candesartan cilexetil